|
1
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carpenter G and Cohen S: 125I-labeled
human epidermal growth factor. Binding, internalization and
degradation in human fibroblasts. J Cell Biol. 71:159–171. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stoscheck CM and Carpenter G: Down
regulation of epidermal growth factor receptors: Direct
demonstration of receptor degradation in human fibroblasts. J Cell
Biol. 98:1048–1053. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hendriks BS, Opresko LK, Wiley HS and
Lauffenburger D: Coregulation of epidermal growth factor
receptor/human epidermal growth factor receptor 2 (HER2) levels and
locations: Quantitative analysis of HER2 overexpression effects.
Cancer Res. 63:1130–1137. 2003.PubMed/NCBI
|
|
5
|
Hommelgaard AM, Lerdrup M and van Deurs B:
Association with membrane protrusions makes ErbB2 an
internalization-resistant receptor. Mol Biol Cell. 15:1557–1567.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Worthylake R, Opresko LK and Wiley HS:
ErbB-2 amplification inhibits down-regulation and induces
constitutive activation of both ErbB-2 and epidermal growth factor
receptors. J Biol Chem. 274:8865–8874. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Citri A, Skaria KB and Yarden Y: The deaf
and the dumb: The biology of ErbB-2 and ErbB-3. Exp Cell Res.
284:54–65. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tikhomirov O and Carpenter G: Geldanamycin
induces ErbB-2 degradation by proteolytic fragmentation. J Biol
Chem. 275:26625–26631. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu W, Mimnaugh E, Rosser MF, Nicchitta C,
Marcu M, Yarden Y and Neckers L: Sensitivity of mature Erbb2 to
geldanamycin is conferred by its kinase domain and is mediated by
the chaperone protein Hsp90. J Biol Chem. 276:3702–3708. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou P, Fernandes N, Dodge IL, Reddi AL,
Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V and Band H: ErbB2
degradation mediated by the co-chaperone protein CHIP. J Biol Chem.
278:13829–13837. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raja SM, Clubb RJ, Bhattacharyya M, Dimri
M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V
and Band H: A combination of Trastuzumab and 17-AAG induces
enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2
degradation and cytotoxicity in ErbB2-overexpressing breast cancer
cells. Cancer Biol Ther. 7:1630–1640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lerdrup M, Hommelgaard AM, Grandal M and
van Deurs B: Geldanamycin stimulates internalization of ErbB2 in a
proteasome-dependent way. J Cell Sci. 119:85–95. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Austin CD, De Mazière AM, Pisacane PI, van
Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J and Scheller RH:
Endocytosis and sorting of ErbB2 and the site of action of cancer
therapeutics trastuzumab and geldanamycin. Mol Biol Cell.
15:5268–5282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Powers MV and Workman P: Targeting of
multiple signalling pathways by heat shock protein 90 molecular
chaperone inhibitors. Endocr Relat Cancer. 13(Supply 1): S125–S135.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fukuyo Y, Hunt CR and Horikoshi N:
Geldanamycin and its anti-cancer activities. Cancer Lett.
290:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sain N, Krishnan B, Ormerod MG, De Rienzo
A, Liu WM, Kaye SB, Workman P and Jackman AL: Potentiation of
paclitaxel activity by the HSP90 inhibitor
17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma
cell lines with high levels of activated AKT. Mol Cancer Ther.
5:1197–1208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Banerji U, Sain N, Sharp SY, Valenti M,
Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, et al:
An in vitro and in vivo study of the combination of the heat shock
protein inhibitor 17-allylamino-17-demethoxygeldanamycin and
carboplatin in human ovarian cancer models. Cancer Chemother
Pharmacol. 62:769–778. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu L, Hofmann J, Lu Y, Mills GB and Jaffe
RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy
of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer
Res. 62:1087–1092. 2002.PubMed/NCBI
|
|
19
|
Wu X, Wanders A, Wardega P, Tinge B, Gedda
L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, et
al: Hsp90 is expressed and represents a therapeutic target in human
oesophageal cancer using the inhibitor
17-allylamino-17-demethoxygeldanamycin. Br J Cancer. 100:334–343.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nygren PA: Alternative binding proteins:
Affibody binding proteins developed from a small three-helix bundle
scaffold. FEBS J. 275:2668–2676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Friedman M and Ståhl S: Engineered
affinity proteins for tumour-targeting applications. Biotechnol
Appl Biochem. 53:1–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baum RP, Prasad V, Müller D, Schuchardt C,
Orlova A, Wennborg A, Tolmachev V and Feldwisch J: Molecular
imaging of HER2-expressing malignant tumors in breast cancer
patients using synthetic 111In- or 68Ga-labeled affibody molecules.
J Nucl Med. 51:892–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ahlgren S, Orlova A, Wallberg H, Hansson
M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V and
Feldwisch J: Targeting of HER2-expressing tumors using
111In-ABY-025, a second-generation affibody molecule with a
fund-amentally reengineered scaffold. J Nucl Med. 51:1131–1138.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lindegren S, Frost S, Bäck T, Haglund E,
Elgqvist J and Jensen H: Direct procedure for the production of
211At-labeled antibodies with an epsilon-lysyl-3
(trimethylstannyl)benzamide immunoconjugate. J Nucl Med.
49:1537–1545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wallberg H and Orlova A: Slow
internalization of anti-HER2 synthetic affibody monomer
111In-DOTA-ZHER2:342-pep2: Implications for development of labeled
tracers. Cancer Biother Radiopharm. 23:435–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gartner EM, Silverman P, Simon M, Flaherty
L, Abrams J, Ivy P and Lorusso PM: A phase II study of
17-allylamino-17-demethoxygeldanamycin in metastatic or locally
advanced, unresectable breast cancer. Breast Cancer Res Treat.
131(3): 933–7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pedersen KS, Kim GP, Foster NR,
Wang-Gillam A, Erlichman C and McWilliams RR: Phase II trial of
gemcitabine and tanespimycin (17AAG) in metastatic pancreatic
cancer: a Mayo Clinic Phase II Consortium study. Invest New Drugs.
33(4): 963–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oki Y, Copeland A, Romaguera J, Fayad L,
Fanale M, Sde C Faria, Medeiros LJ, Ivy P and Younes A: Clinical
experience with the heat shock protein-90 inhibitor, tanespimycin,
in patients with relapsed lymphoma. Leuk Lymphoma. 53(5): 990–2.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shih LB, Thorpe SR, Griffiths GL, Diril H,
Ong GL, Hansen HJ, Goldenberg DM and Mattes MJ: The processing and
fate of antibodies and their radiolabels bound to the surface of
tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med.
35:899–908. 1994.PubMed/NCBI
|
|
30
|
Tolmachev V: Chapter 8: Choice of
Radionuclides and Radiolabelling TechniquesTargeted Radionuclide
Tumor Therapy - Biological Aspects. Stigbrand T, Carlsson J and
Adams GP: Springer; pp. 145–174. 2008, View Article : Google Scholar
|
|
31
|
Hartman T, Lundqvist H, Westlin JE and
Carlsson J: Radiation doses to the cell nucleus in single cells and
cells in micro-metas-tases in targeted therapy with (131)I labeled
ligands or antibodies. Int J Radiat Oncol Biol Phys. 46:1025–1036.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wilbur S: Chemical and Radiochemical
Considerations in Radiolabeling with-Emitting Radionuclides.
Current Pharmaceuticals. 4:214–247. 2011. View Article : Google Scholar
|
